Clinical Trials Logo

Clinical Trial Summary

This is a two-arm Phase 1b feasibility trial consisting of 20 patients receiving the combination of ipilimumab+nivolumab, either adjuvant, or split neo-adjuvant and adjuvant.


Clinical Trial Description

Patients with stage III melanoma with palpable disease, naïve for CTLA-4/PD-1/PD-L1 immunotherapy, will be treated either post-surgery for 12 weeks with the combination of ipilimumab+nivolumab or in a split design for 6 weeks upfront surgery and for 6 weeks postsurgery. It is a two-arm Phase 1b feasibility trial consisting of 20 patients, 10 in each arm. At different timepoints tumor biopsies and blood for PBMCs will be taken for translational research. Also scans will be done on specific timepoints. The study will be held to determine safety, feasibility, and the immune-activating capacity of short-term combined neo-adjuvant and adjuvant ipilimumab + nivolumab. And to determine relapse free survival (RFS), any late adverse events, pharmacokinetics/pharmacodynamics, and the correlation between RFS and changes in neo-antigen specific T cell response. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02437279
Study type Interventional
Source The Netherlands Cancer Institute
Contact
Status Active, not recruiting
Phase Phase 1
Start date November 24, 2016
Completion date June 2025

See also
  Status Clinical Trial Phase
Completed NCT03229278 - Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma Phase 1
Completed NCT00866177 - MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma Phase 2
Completed NCT03028948 - Interactive Tailored Website to Promote Sun Protection and Skin Self-Check Behaviors in Patients With Melanoma N/A
Completed NCT03112668 - Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners N/A
Active, not recruiting NCT03154190 - Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer N/A
Completed NCT00387751 - Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma Phase 2